Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RioDerm-001
- Development stage
- Unknown
- Lead developer
- RION
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Topical
01
Overview
RioDerm-001 is an investigational biologic therapy under development for the treatment of diabetic foot ulcers. It consists of platelet-derived exosomes containing fibrin, formulated as a powder and administered topically. The drug is based on Purified Exosome Product (PEP) technology, which aims to harness the regenerative properties of exosomes for wound healing and tissue repair. The developer, Rion, is a clinical-stage biotechnology company focused on exosome-based therapies for various indications in regenerative medicine[1][3].
Beyond the preview
Go deeper on RioDerm-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RioDerm-001.